Cynthia A. Challener

Increases in efficiencies, flexibility, scalability, and sustainability are impacting adoption.

Proprietary cell lines offer opportunities for achieving high AAV titers.

Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.

Developing freeze-drying processes requires patience and deep product and process understanding.

Product and process understanding are essential to effective resin selection.

A look at how linker technology for antibody drug conjugates has evolved.

Preparing for variability and flexible processing are necessary for success.

There is no such thing as a perfect linker.

Using a systematic approach and achieving run-to-run consistency are essential.

Process and bioreactor performance are directly impacted by real-time monitoring capabilities.